Oncology Nurse Advisor16h
Adjuvant Nivolumab Improves Outcomes in High-Risk MIUC
Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Bicycle Therapeutics plc (NASDAQ:BCYC) announced that it presented data showing the enhanced anti-tumor activity of ...
Medindia9d
Cell-Free DNA in Urine: A New Biomarker for UTUC Detection
Discover how voided urine cfDNA emerges as a promising biomarker for upper tract urothelial carcinoma, offering a less ...
Business Wire13d
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that ...